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Abstract 
BACKGROUND: Erythema elevatum diutinum (EED) belongs to the spectrum of cutaneous leukocytoclastic 
vasculitides. EED is a very rare dermatosis presenting with reddish to browning papules and plaques. EED may 
be associated with infections, hematologic and autoimmune disorders. 
CASE REPORTS: We present two patients with EED, a 50-year-old woman and a 42-year-old man. While the 
woman shows an association with colitis ulcerosa, the man had an anti-thrombin deficiency. Treatment was 
started with oral corticosteroid and dapsone, respectively. In both cases, there was a partial and temporary 
response. 
CONCLUSIONS: EED is a rare vasculitis with an unusual clinical presentation and a chronic course. Response to 
treatment is unsatisfactory and in the long-term run sometimes frustrating. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Erythema elevatum diutinum (EDD) belongs 
to the heterogeneous group of cutaneous 
leukocytoclastic vasculitides. It is a rare disorder, with 
less than 150 cases reported worldwide. It runs a 
chronic course with a fluctuating severity [1].  
The characteristic clinical features are often 
symptomless plaques and nodules with a preference 
of extensor areas. There is neither a racial nor gender 
preference. The peak incidence seems to be in the 
fourth to the sixth decade [2]. 
Histologically, the disease is a leuko-
cytoclastic vasculitis of the mid and upper dermis. 
Polymorphonuclear cells, macrophages, histiocytes 
dominate the infiltrate. Some eosinophils may be 
present. In the early stage, there is papillary oedema 
causing pseudo-vesiculation. In long-standing lesions, 
dermal vessels become dilatated with hypertrophic 
and sometimes protruding endothelial cells. 
Sometimes nodular lesions may be present containing 
spindle cells which are expressing Mac-387. Immune 
complexes may become deposited, and granulomas 
can appear [3], [4]. 
Infections have been associated with EED 
such as human deficiency virus and AIDS, hepatitis B 
or syphilis [5], [6]. There are several reports on the 
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association of EED with haematological disorders 
such as clonal gammopathy, or autoimmune 
connective tissue diseases like lupus erythematosus, 
dermatomyositis, chronic inflammatory bowel disease, 
Wegener’s granulomatosis or relapsing polychondritis 
[2]. Cocaine adulterated with levamisole can induce 
an EED-like vasculitis [7]. 
 
 
Case Report 
 
Case 1 
A 50-years-old woman presented with chronic 
plaques on the extensor surface of both hands for four 
years. Sometimes, she noted swelling of the hands or 
suggillations into the plaques. She suffered from 
colitis ulcerosa. More than 10 years ago a colectomy 
had been performed. She was treated with ispaghula 
(Psylla seeds), loperamide, tolterodine tartrate, and 
topical intra-anal corticosteroid foam.  
On examination, we observed multiple 
erythematous-livid nodules and plaques of a relatively 
soft consistency on the back of her hands (Figure 1). 
 
Figure 1: Erythema elevatum diutinum late-stage lesion on the 
hands (case 1) 
 
Laboratory investigations: Anti-thrombin was 
reduced with 54% (normal range: 75-125), slightly 
increased were gamma globulins 13.5% (7.2-11.3) 
and lactate dehydrogenase 3.85 µkat/L (2.25-3.55). 
Negative or in the normal range were an immune 
fixation, HIV-antibodies, cardiolipin antibodies, and 
rheumatoid factor.  
Imaging (endo-sonography, sigmoidoscopy, 
abdominal magnetic resonance imaging (MRI)) was 
unremarkable, except for a pouchitis. 
Histopathology from a skin biopsy revealed 
increased vascularity (mainly post-capillary venules) 
embedded in a slightly fibrotic connective tissue. 
Perivascular infiltrates consisted of lymphocytes, 
monocytes, and some neutrophils (Figure 2). 
 
Figure 2: Histopathology of erythema elevatum diutinum (Case 1); 
A) Hematoxylin-eosin (x 10); B) Giemsa stain (x 20) 
 
The findings were interpreted as a late stage 
of EED. We compared our findings with an external 
histopathology report 3 years ago, where the lesions 
demonstrated the characteristic leukocytoclastic 
vasculitis signs.  
We initiated oral treatment with 
methylprednisolone 32 mg/day and topical treatment 
with clobetasol 0.05% ointment. The lesions became 
flatter, but the patient developed arterial hypertension 
and headaches. The internal corticosteroid therapy 
was stopped. Neither cyclosporine A nor methotrexate 
were effective. Dapsone 100 mg/day was not 
tolerated due to increased meth-haemoglobin levels. 
 
Case 2 
Two years ago, a 42-years-old man 
developed some papules on the knees with minimal 
pruritus. Dark red and livid papules and plaques 
appeared on arms. The course was characterized by 
waxing and waning. His medical history was otherwise 
unremarkable. He had no medical drug treatment. 
On examination, we observed multiple 
erythematous to brownish asymptomatic papules on 
the extremities (knees, forearms, elbows, and back of 
the hands). The maximum diameter was 2 cm. Some 
of the lesions disappeared, leaving atrophic scars 
(Figure 3). 
A skin biopsy demonstrated upper dermal 
leukocytoclastic vasculitis and massive neutrophilic 
nuclear debris and discrete extravasates of 
erythrocytes. 
Laboratory investigations were unremarkable. 
Antinuclear antibodies, paraproteins, and anti-
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streptolysin titer were negative. 
 
Figure 3: Erythema elevatum diutinum – earlier lesions (Case 2) 
 
The diagnosis of EED was confirmed. 
We initiated oral treatment with dapsone 100 
mg/day. Lesions showed regression leaving 
hyperpigmented scars. After dose reduction, a partial 
relapse was observed, and the dose was increased to 
100 mg per day. 
 
 
Discussion 
 
EED is a rare leukocytoclastic vasculitis of the 
mid and upper dermis, that can be associated with 
underlying disorders like autoimmune diseases, 
haematological conditions or chronic infections [1], [2]. 
It has a good prognosis in contrast to systemic 
leukocytoclastic vasculitides although the course is 
chronic [8]. 
We report on EED with two different clinical 
patterns – A) the classical nodules and plaques 
overlying the joints of upper extremities and B) 
disseminated papules on legs and arms. Rarely, 
vesicobullous lesions have been reported suggesting 
Sweet syndrome [9]. 
The course of the disease is characterized by 
chronicity with waxing and waning of lesions. We 
presented a late-stage and an earlier stage of EED. 
The characteristics of leukocytoclastic vasculitis are 
seen in earlier lesions with prominent endothelial 
cells, but they get lost, and the perivascular 
connective tissue becomes fibrotic [3], [4].  
The most commonly used therapy is oral 
dapsone, with a response rate of up to 80%. The drug 
inhibits neutrophil chemotaxis and function. A 
complete resolution is hot always possible. In nodular 
lesions, this drug has only limited efficacy. Many 
patients with nodules do not respond [2].  
Dapsone is contraindicated in patients with a 
glucose-6-phosphate deficiency where it can cause 
severe hemolytic anaemia. Dapsone hypersensitivity 
is another important adverse effect. Pancytopenia has 
occasionally been observed [10], 
Second-line therapies are systemic 
corticosteroids, colchicine, methotrexate, chloroquine 
and anti-retroviral drugs in case of HIV-associated 
EED. Antimicrobials with suppressive effects on 
neutrophils such as tetracyclines, erythromycin or 
sulfonamides have been used in single cases with 
success. Nicotinamide may be used in combination 
with tetracyclines or as a single drug. Topical therapy 
with corticosteroids, retinoids or dapsone is of limited 
value [11].  
In conclusion, EED is part of the spectrum of 
leukocytoclastic vasculitides of skin. Although the 
lesions are commonly asymptomatic, they are 
disfiguring, and treatment is demanded. Based on 
experience, dapsone is the most often used drug. In 
the long-term run, however, medical treatment of EED 
is unsatisfactory and sometimes frustrating. 
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